Effect of Timed-Restricted Eating on Metabolic Health (TREAT)
The Effect of Timed-Restricted Eating on Insulin Sensitivity, De Novo Lipogenesis and Liver Fat in Subjects With Obesity and Insulin Resistance
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Jur Kroon, BSc
- Phone Number: +31 683238752
- Email: jur.kroon@amsterdamumc.nl
Study Contact Backup
- Name: Sarah E Siegelaar, MD PhD
- Email: s.e.siegelaar@amsterdamumc.nl
Study Locations
-
-
Noord-Holland
-
Amsterdam, Noord-Holland, Netherlands, 1105AZ
- Recruiting
- Amsterdam UMC, location AMC
-
Contact:
- Jur Kroon, BSc
- Phone Number: +31 683238752
- Email: jur.kroon@amsterdamumc.nl
-
Sub-Investigator:
- Jur Kroon, BSc
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Ability to provide informed consent;
- BMI > 30kg/m^2;
- Insulin resistance, as defined by fasting plasma insulin > 62 pmol/L and/or prediabetes, as defined by fasting plasma glucose > 5.3 and < 7.0 mmol/L;
- Stable weight for 3 months prior to study inclusion
- For women, 1 year after last menstrual cycle
Exclusion Criteria:
- Use of any medication, except for those related to treatment of metabolic syndrome;
- Any medical condition interfering with study outcomes or design;
- History of any psychiatric disorder, including eating disorders;
- Performing shift work
- Performing intensive sports (>3 hours/week);
- Smoking;
- Drugs abuse or alcohol abuse (>3 units/day);
- Contraindication for MRI;
- Known lactose/gluten intolerance;
- Known soy, egg, milk or peanut allergy;
- Childhood onset of obesity
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Early time-restricted eating
|
Subjects will follow an isocaloric diet, designed by a dietician.
The eating window for the early-TRE group is between 7 AM - 5 PM
Other Names:
|
|
Experimental: Late time-restricted eating
|
Subjects will follow an isocaloric diet, designed by a dietician.
The eating window for the late-TRE group is between 10 AM - 8 PM
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Insulin Sensitivity
Time Frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
|
We will use the Oral Minimal Model Method in conjunction with a Mixed Meal Tolerance Test (MMTT) to quantitatively evaluate insulin sensitivity.
Concentrations of insulin, glucose, and C-peptide will be measured during the course of the MMTT to serve as the requisite inputs for the model.
The output is in dl/kg/min/uU/ml.
|
Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in plasma insulin
Time Frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
|
Fasted and stimulated insulin (pmol/L) will be measured during MMTT
|
Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
|
|
Change in plasma glucose
Time Frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
|
Fasted and stimulated glucose (mmol/L) will be measured during MMTT
|
Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
|
|
Change in intrahepatic fat
Time Frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
|
To quantify the intrahepatic fat content, a single voxel 1H-MRS (magnetic resonance spectroscopy) will be used.
Relative fat content will be expressed as the ratio of the fat peak over the cumulative fat and water peak.
This will also be corrected for T2 relaxation.
|
Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
|
|
Change in beta cell function (C-peptide)
Time Frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
|
Fasted and stimulated C-peptide (nmol/L) will be measured during MMTT
|
Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
|
|
Change in insulin aignaling
Time Frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
|
Biopsies will be taken from skeletal muscle and subcutaneous fat to measure key proteins in the insulin signalling pathway (Western blots)
|
Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
|
|
Change in glucose variability
Time Frame: Baseline 1 to week 4 for intervention 1, Baseline 2 to week 12 for intervention 2
|
In our study, we will deploy Continuous Glucose Monitors (CGMs) to acquire an in-depth understanding of glucose variability in participants throughout the course of the intervention.
These monitors gauge glucose concentrations in the interstitial fluid (mmol/L), serving as a reliable proxy for blood glucose levels.
This approach will enable us to assess key metrics such as mean, minimum and maximum glucose levels.
|
Baseline 1 to week 4 for intervention 1, Baseline 2 to week 12 for intervention 2
|
|
De novo lipogenesis
Time Frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
|
Fasted and stimulated de novo lipogenesis (DNL) will be measured during the MMT as 2H incorporation into fatty acids following deuterated water (2H2O) administration
|
Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
|
|
Immunological markers
Time Frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
|
We will conduct immune cell phenotyping on whole blood samples to identify and categorize various immune cell types.
Additionally, we will assess immune cell function and metabolism in isolated peripheral blood mononuclear cells (PBMCs).
Inflammatory markers will also be assessed in serum samples to provide a comprehensive overview of immune and inflammatory status.
|
Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
|
|
Physical activity
Time Frame: Baseline 1 to week 4 for intervention 1, Baseline 2 to week 12 for intervention 2
|
Physical activity will be assessed via accelerometry.
Accelerometry represents the magnitude of acceleration in any direction, over a predefined epoch.
|
Baseline 1 to week 4 for intervention 1, Baseline 2 to week 12 for intervention 2
|
|
Functional brain activity
Time Frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
|
Brain activation maps and functional connectivity will be assessed by blood oxygen dependent signals in the resting state and after visual food cues using functional magnetic resonance imaging (fMRI).
|
Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
|
|
Psychological factor - Food Craving
Time Frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
|
We will use the General Food Cravings Questionnaire (G-FCQ) to evaluate the frequency and intensity of food cravings among participants.
The scoring for the G-FCQ ranges between 21 and 105, with higher scores indicative of more pronounced food craving tendencies.
|
Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
|
|
Psychological factor - Eating behaviour
Time Frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
|
We will utilize the Dutch Eating Behavior Questionnaire (NVE) to assess and categorize the eating behaviors and tendencies of our participants.
The NVE discerns three distinct eating styles: emotional eating, external eating, and restrained eating.
A higher score within a specific style suggests a predominant inclination towards that particular eating behavior.
|
Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
|
|
Psychological factor - Hunger scale
Time Frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
|
We will employ a nine-question visual analogue scale (VAS) to assess hunger.
Each question will be scored 0-100.
|
Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
|
|
Psychological factor - Food addiction
Time Frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
|
We will use the Yale Food Addiction Scale 2.0 (YFAS 2.0) to assess addictive behaviours.
The YFAS 2.0 is designed in accordance with the DSM-5 criteria, and its scoring system mirrors the number of DSM-5 criteria fulfilled indicative of addiction.
|
Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
|
|
Psychological factor - Impulsiveness
Time Frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
|
We will use the Barratt Impulsiveness Scale (BIS) to scale impulsiveness towards food.
This will help us understand how impulsivity might influence dietary behaviour.
The score ranges from 30-120 and a higher score leans towards greater impulsivity.
|
Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
|
|
Psychological factor - Chronotype
Time Frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
|
To determine natural sleep-wake patterns, we will use the Munich Chronotype Questionnaire (MCTQ).
This tool offers a comprehensive understanding of sleep behaviors, revealing a chronotype.
|
Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
|
|
Subject experience with intervention
Time Frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
|
We will employ a semi-structured oral interview as part of our qualitative approach to understand our participants' experience and adherence to the intervention.
|
Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
|
|
Delay discounting computational task
Time Frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
|
The delay discounting task aids in understanding the decision-making processes that might contribute to overeating and poor food choices.
In this task, we will be able to measure the ability of each individual to delay immediate gratification for a greater future reward.
|
Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
|
|
Iowa gambling computational task
Time Frame: Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
|
We use the Iowa gambling task to assess decision-making and risk-reward sensitivity.
Participants choose cards from four decks, each with different reward and punishment rates, aiming to maximize their winnings.
We use this task to study risk taking and impulsive behaviour.
|
Baseline 1 and week 4 for intervention 1; Baseline 2 and week 12 for intervention 2
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Mireille JM Serlie, MD PhD, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NL79197.018.21
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.